Geiger Sabine, Hirsch Daniela, Hermann Felix G
Preclinical Development, Apceth Biopharma GmbH, Munich, Germany
Preclinical Development, Apceth Biopharma GmbH, Munich, Germany.
Eur Respir Rev. 2017 Jun 28;26(144). doi: 10.1183/16000617.0044-2017. Print 2017 Jun 30.
Besides cancer and cardiovascular diseases, lung disorders are a leading cause of morbidity and death worldwide. For many disease conditions no effective and curative treatment options are available. Cell therapies offer a novel therapeutic approach due to their inherent anti-inflammatory and anti-fibrotic properties. Mesenchymal stem/stromal cells (MSC) are the most studied cell product. Numerous preclinical studies demonstrate an improvement of disease-associated parameters after MSC administration in several lung disorders, including chronic obstructive pulmonary disease, acute respiratory distress syndrome and idiopathic pulmonary fibrosis. Furthermore, results from clinical studies using MSCs for the treatment of various lung diseases indicate that MSC treatment in these patients is safe. In this review we summarise the results of preclinical and clinical studies that indicate that MSCs are a promising therapeutic approach for the treatment of lung diseases. Nevertheless, further investigations are required.
除癌症和心血管疾病外,肺部疾病是全球发病和死亡的主要原因。对于许多疾病状况,尚无有效的治愈性治疗选择。细胞疗法因其固有的抗炎和抗纤维化特性而提供了一种新颖的治疗方法。间充质干/基质细胞(MSC)是研究最多的细胞产品。大量临床前研究表明,在包括慢性阻塞性肺疾病、急性呼吸窘迫综合征和特发性肺纤维化在内的几种肺部疾病中,给予MSC后疾病相关参数有所改善。此外,使用MSC治疗各种肺部疾病的临床研究结果表明,在这些患者中进行MSC治疗是安全的。在本综述中,我们总结了临床前和临床研究的结果,这些结果表明MSC是治疗肺部疾病的一种有前景的治疗方法。然而,仍需要进一步的研究。